CLRB
Cellectar Biosciences, Inc.
NASDAQ · USHealthcareBiotechnology
$2.52+0.40%
Price as of Jul 20, 2026
CLRB financials
Cellectar Biosciences, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $213.6K | $0.00 | $0.00 | $0.00 |
| Gross profit | -$213.6K | $0.00 | $0.00 | $0.00 |
| Operating expenses | $22.8M | $51.8M | $39.0M | $28.8M |
| Operating income | -$23.0M | -$51.8M | -$39.0M | -$28.8M |
| Net income | -$21.8M | -$44.6M | -$42.8M | -$31.8M |
| EBITDA | -$21.6M | -$44.2M | -$42.6M | -$31.7M |
| Basic EPS | $-8.35 | $-36.52 | $-104.99 | $-135.18 |
| Diluted EPS | $-8.35 | $-41.89 | $-104.99 | $-135.18 |
| Balance sheet | ||||
| Cash & equivalents | $13.2M | $23.3M | $9.6M | $19.9M |
| Total assets | $15.0M | $25.5M | $12.1M | $21.6M |
| Total liabilities | $5.1M | $11.2M | $25.9M | $12.1M |
| Stockholders’ equity | $9.9M | $14.3M | -$13.8M | $9.5M |
| Total debt | $409.6K | $494.0K | $553.0K | $603.8K |
| Net debt | -$12.8M | -$22.8M | -$9.0M | -$19.3M |
| Cash flow | ||||
| Operating cash flow | -$23.1M | -$47.6M | -$32.4M | -$25.2M |
| Capital expenditure | -$5.9K | -$104.2K | -$864.0K | -$226.0K |
| Free cash flow | -$23.1M | -$47.7M | -$33.2M | -$25.4M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |